Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients

Journal of Infection

Volumn 62, Issue 4, 2011, Pages 319-321

  Fabbiani, Massimiliano ^a   Bracciale, Laura ^a   Doino, Maria ^a   D'Avino, Alessandro ^a   Marzocchetti, Angela ^a   Navarra, Pierluigi ^a   Cauda, Roberto ^a   De Luca, Andrea ^a,b   Di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CREATININE; LAMIVUDINE; RITONAVIR; TENOFOVIR;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FLANK PAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; URINALYSIS; UROLITHIASIS;

ADENINE; ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; UROLITHIASIS;

EID: 79953049661     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.02.004     Document Type: Letter

References (13)

1. Kopp J.B., Miller K.D., Mican J.A., Feuerstein I.M., Vaughan E., Baker C., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997, 127:119-125.
2. Doco-Lecompte T., Garrec A., Thomas L., Trechot P., May T., Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004, 18:705-706.
3. Chang H.R., Pella P.M. Atazanavir urolithiasis. N Eng J Med 2006, 355:2158-2159.
4. Pacanowski J., Poirier J.M., Petit I., Meynard J.L., Girard P.M. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006, 20:2131.
5. Anderson P.L., Lichtenstein K.A., Gerig N.E., Kiser J.J., Bushman L.R. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS 2007, 21:1060-1062.
6. Chan-Tack K.M., Truffa M.M., Struble K.A., Birnkrant D.B. Atazanavir-associated nephrolithiasis: cases from the US food and drug administration's adverse event reporting system. AIDS 2007, 21:1215-1218.
7. D'Ettorre G., Zaffiri L., Ceccarelli G., Massetti A.P., Mastroianni C.M., Vullo V. Urolithiasis under atazanavir boosted and tenofovir therapy: a case report. J Chemother 2008, 20:143-144.
8. Atazanavir/ritonavir and lamivudine for treatment simplification, AtLaS study. Available at: [accessed 20.01.11]. http://clinicaltrials.gov/ct2/show/NCT00885482.
9. Fabbiani M., Bracciale L., Doino M., Sidella L., Farina S., Di Cristo V., et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother 2011, 66:682-683.
10. Fabbiani M., Di Giambenedetto S., Bracciale L., Bacarelli A., Ragazzoni E., Cauda R., et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009, 64:109-117.
11. Di Giambenedetto S., De Luca A., Villani P., Bacarelli A., Ragazzoni E., Regazzi M., et al. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. HIV Med 2008, 9:239-245.
12. Taburet A.M., Piketty C., Chazallon C., Vincent I., Gérard L., Calvez V., et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004, 48:2091-2096.
13. Fabbiani M., Di Giambenedetto S., Ragazzoni E., Colafigli M., Prosperi M., Cauda R., et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med 2010, 11:326-333.